Adhexil is a human fibrin-based sealant after gynecological surgery.
Omrix Biopharmaceuticals Ltd. (Nasdaq:OMRI) has launched its Phase I/II clinical trial of Adhexil, a proprietary adhesion prevention product. The study will evaluate the safety and initial efficacy of Adhexil in preventing and/or reducing post-operative adhesions in patients undergoing gynecological surgery of the ovaries. The one-year clinical trial will enroll 25 patients with bilateral ovarian disease and identified adhesions and will be conducted at four centers in Europe and the US.
Adhexil is delivered in a kit containing a human, fibrin-based, absorbable, adhesion barrier. Adhexil can be sprayed on surfaces most at risk for adhesions at the end of the surgical procedure.
Published by Globes [online], Israel business news - www.globes.co.il - on October 29, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007